BCYC:NSD-Bicycle Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 46.63

Change

-0.02 (-0.04)%

Market Cap

USD 1.42B

Volume

0.22M

Avg Analyst Target

USD 68.70 (+47.33%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Bicycle Therapeutics plc (BCYC) Stock Analysis:
Based on the Bicycle Therapeutics plc stock forecasts from 8 analysts, the average analyst target price for Bicycle Therapeutics plc is USD 68.70 over the next 12 months. Bicycle Therapeutics plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bicycle Therapeutics plc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Bicycle Therapeutics plc’s stock price was USD 46.63. Bicycle Therapeutics plc’s stock price has changed by -4.14% over the past week, -9.87% over the past month and +64.77% over the last year.

About

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

USD17.76B N/A N/A

ETFs Containing BCYC

Symbol Name Weight Mer Price(Change) Market Cap
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

-0.36 (-1.15%)

USD0.03B
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

-0.17 (-0.87%)

USD0.03B
AADR AdvisorShares Dorsey Wrig.. 0.00 % 1.10 %

+0.19 (+0.30%)

USD0.08B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.39% 23% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.39% 23% F 11% F
Trailing 12 Months  
Capital Gain 64.77% 96% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.77% 96% A 94% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 71.47% 83% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.47% 83% B 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 65.57% 45% F 25% F
Risk Adjusted Return 109.01% 100% A+ 96% A
Market Capitalization 1.42B 84% B 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1,839.00 1% F 1% F
Price/Book Ratio 8.98 11% F 13% F
Price / Cash Flow Ratio -80.06 96% A 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -47.23% 59% F 28% F
Return on Invested Capital -50.44% 47% F 17% F
Return on Assets -17.90% 70% C- 22% F
Debt to Equity Ratio 15.19% 45% F 64% D
Technical Ratios  
Short Ratio 2.16 62% D- 52% F
Short Percent 3.53% 58% F 42% F
Beta -0.26 96% A 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.